Scombroid Fish PoisoningMANAGEMENT

ENVIRONMENTAL AND EXPOSURE PRESENTATIONS · 12 SECTIONS

⚲

606 items

☷ Legend

⚲

Cardiovascular Presentations71▾

Respiratory Presentations52▾

Neurological Presentations83▾

Gastrointestinal Presentations74▾

Genitourinary and Reproductive Presentations48▾

Infectious Disease Presentations148▾

Trauma Presentations89▾

Toxicologic Presentations80▾

Psychiatric Presentations26▾

Musculoskeletal and Rheumatologic Presentations96▾

Dermatology Presentations23▾

Environmental and Exposure Presentations27▾

Acute Mountain Sickness Arterial Gas Embolism Bee-Wasp Sting (Anaphylaxis)Chilblains Ciguatera Fish Poisoning Coral Cut Decompression Sickness Electrical Burn Injury Envenomation (snake, spider, insect)High Altitude Cerebral Edema (HACE)High Altitude Pulmonary Edema (HAPE)High-altitude illness Hypothermia Hypothermia (Mild)Hypothermia (Severe)Immersion Foot Lightning Strike Injury Scombroid Fish Poisoning Scorpion Envenomation Sea Urchin Injury Shark Bite Snake Envenomation Spider Bite (Black Widow)Spider Bite (Brown Recluse)Stingray Spine Injury Tick paralysis White Phosphorus Burn

Hematologic and Oncologic Presentations36▾

Pediatric-Specific Presentations19▾

Endocrine and Metabolic Presentations45▾

ENT and Maxillofacial Presentations27▾

Ophthalmologic Presentations19▾

Obstetric Presentations23▾

Systemic and Miscellaneous Presentations17▾

01Approach to the Critical Patient/attcp54

Immediate priorities

›Airway and anaphylaxis-equivalent threats

›Angioedema of tongue, lips, or oropharynx

›Risk of rapid airway obstruction

›Prepare for definitive airway early

›Bronchospasm or stridor

›SpO2 < 94% on room air

›Audible wheeze or inspiratory stridor

›If airway compromise present, act immediately

›Epinephrine IM without delay

›Anesthesia or critical care at bedside

›Hemodynamic threats

›Vasodilatory shock from massive histamine release

›SBP < 90 mmHg

›MAP < 65 mmHg

›Tachycardia or palpitations

›Sinus tachycardia most common

›Rare malignant arrhythmia — obtain ECG

›IV access and crystalloid bolus for hypotension

›1–2 L normal saline or lactated Ringer

›Escalate to vasopressors if no response

›Key early recognition

›Onset 10–60 minutes after fish ingestion

›Scombridae family or other histidine-rich species

›Cluster of cases after shared meal — critical diagnostic clue

›Toxin-mediated process, not IgE-mediated allergy

›Tryptase normal distinguishes from true anaphylaxis

›Do not label as fish allergy

02History/hx66

Presenting symptoms

›Classic symptom complex

›Flushing — face and upper body, "sunburn-like" appearance

›Onset 10–60 minutes after ingestion

›Most common presenting feature

›Headache — often severe and throbbing

›Direct H1-receptor mediated vasodilation

›Frequently mistaken for allergic cephalalgia

›GI symptoms

›Nausea and vomiting

›Diarrhea and abdominal cramps

›Palpitations and tachycardia

›Pruritus and urticaria

›Neurologic and constitutional symptoms

›Dizziness and lightheadedness

›Blurred vision

›Diaphoresis and hot flushes

›Anxiety or sense of impending doom

Ingestion history

›Fish type and source

›Tuna, mackerel, mahi-mahi, bonito, skipjack — highest risk

›Dark-fleshed fish with high histidine content

›Bluefish, amberjack, anchovies, herring, sardines, marlin also implicated

›Restaurant-prepared, home-prepared, or imported source

›>80% of fish consumed in the US is imported

›Cold-chain breaks common in imported fish

›Peppery, sharp, salty, or "bubbly" taste at time of consumption

›Strongly suggests histamine contamination

03Physical Exam/exam43

Vital signs

›Hemodynamic assessment

›Heart rate — tachycardia almost universal

›Rate >120 bpm warrants cardiac monitoring

›Blood pressure — hypotension in severe cases

›SBP < 90 mmHg triggers anaphylaxis protocol

›Respiratory rate — tachypnea with bronchospasm

›Temperature — typically normal or low-grade

›High fever suggests alternative diagnosis (true food poisoning)

›Oxygen saturation — SpO2 < 94% requires supplemental oxygen

Skin findings

›Characteristic dermatologic pattern

›Diffuse erythematous flushing of face and upper body

›"Sunburn-like" appearance without sun exposure

›Sharp demarcation at mid-torso is characteristic

›Urticaria — raised erythematous wheals

›May be generalized

›Diaphoresis

›Pruritus — often intense

›No target lesions or purpura (differentiates from other rashes)

Head, eyes, ears, nose, and throat

›Facial and oropharyngeal findings

›Facial edema — lips, periorbital tissue

›Angioedema in severe cases

›Tongue swelling — indicates risk of airway compromise

›Conjunctival injection and tearing

›Oropharyngeal erythema without exudate

›Exudate suggests alternative pharyngeal pathology

04Differential Diagnosis/ddx47

Allergic and immunologic mimics

›IgE-mediated fish allergy (T78.1 ICD-10)

›Most important mimic — management differs substantially

›Scombroid: normal tryptase, cluster of cases, prior fish tolerance

›True allergy: elevated tryptase, single patient, positive specific IgE

›Distinguishing: scombroid patients do NOT need future fish avoidance

›Anaphylaxis from other triggers (T78.2)

›Elevated tryptase (>11 ng/mL) within 1–2 hours supports true anaphylaxis

›Normal tryptase strongly favors scombroid

›Single patient, no meal-sharing history

›Mast cell activation syndrome / systemic mastocytosis (D47.09)

›Recurrent episodic flushing, urticaria, GI symptoms

›Elevated baseline tryptase

›No clear fish ingestion trigger required

Marine toxin poisoning mimics

›Ciguatera fish poisoning (T61.01)

›Large reef fish: barracuda, grouper, snapper

›Neurologic symptoms predominate: paresthesias, temperature reversal

›Longer symptom duration — days to weeks

›No flushing or urticaria

›Paralytic shellfish poisoning (T61.2)

›Rapid onset neurologic symptoms after shellfish

›Paresthesias, ascending paralysis

›No flushing

›Tetrodotoxin poisoning (T61.771)

›Puffer fish ingestion

›Neurologic and paralytic features

›No histaminergic symptoms

05Laboratory Tests/lt43

Serum tryptase

›Tryptase — key differentiating test

›Draw within 1–2 hours of symptom onset

›Normal in scombroid: <11 ng/mL

›Elevated in true anaphylaxis: >11 ng/mL

›Clinical implication

›Normal tryptase in symptomatic patient strongly favors scombroid

›Elevated tryptase mandates allergy workup and epinephrine auto-injector prescription

›Evidence basis

›Ricci et al., Clinical Toxicology 2010 — validated tryptase as scombroid indicator

Histamine levels

›Plasma histamine

›Elevated in scombroid but impractical for acute use

›Very labile — short half-life of minutes

›Requires immediate processing in ice-chilled tubes

›Not routinely recommended in the ED

›Urinary histamine metabolites

›N-methylhistamine in 24-hour urine

›Can confirm histamine exposure retrospectively

›Useful for public health and epidemiologic confirmation

›Rarely needed acutely

Fish histamine analysis

›Implicated fish sample testing

›FDA action level >50 mg histamine per 100g fish

›Confirms batch contamination

›Performed by FDA or state health departments

›Public health investigation tool

›Save leftover fish from implicated meal

06Diagnostic Tests/dt41

Scoring Systems

›No validated scombroid-specific scoring system exists

›Severity stratification — clinical framework

›Mild: flushing, headache, mild GI symptoms — spontaneous resolution possible

›Moderate: urticaria, persistent GI symptoms, palpitations — responds to antihistamines

›Severe: hypotension, bronchospasm, angioedema, arrhythmia — anaphylaxis protocol

›Anaphylaxis grading (Ring and Messmer Classification)

›Grade I: skin and mucosal signs only

›Grade II: measurable but non-life-threatening reactions

›Grade III: life-threatening bronchospasm or hypotension

›Grade IV: cardiorespiratory arrest

›Brighton Collaboration anaphylaxis case definition

›Applied when true anaphylaxis cannot be excluded

›Level 1: acute reaction with skin/mucosal + respiratory or cardiovascular

›Level 2: skin/mucosal + one other system involved

›Level 3: acute reaction without skin involvement

MRI

›MRI — not indicated for scombroid poisoning

›No established role in standard evaluation

›Brain MRI only if neurologic symptoms atypical for scombroid

›Ciguatera or other neurotoxic etiology suspected in atypical case

›Cardiac MRI consideration

›If Kounis syndrome with myocardial involvement suspected after acute phase

›Late gadolinium enhancement to assess for infarction pattern

›CT — rarely indicated

›Chest CT consideration

›Significant respiratory compromise not explained by bronchospasm alone

07Disposition/dispo40

Discharge criteria

›Criteria for safe discharge

›Symptom resolution after antihistamine treatment

›No flushing, urticaria, or GI symptoms

›Headache resolved or well-controlled

›Hemodynamic stability

›SBP > 100 mmHg without fluid support

›Heart rate < 100 bpm

›Tolerating oral fluids without vomiting

›Observation period completed

›Minimum 2–4 hours after symptom onset

›Longer if parenteral treatment required

Admission criteria

›Indications for inpatient admission

›Hemodynamic instability

›Hypotension requiring IV fluids or vasopressors

›Arrhythmia requiring monitoring

›Respiratory compromise

›Bronchospasm not resolved after albuterol and epinephrine

›Angioedema of upper airway

›Repeated dosing without improvement

›Refractory urticaria or vomiting despite antihistamines

›Significant comorbidities

›Severe asthma with exacerbation

›Cardiac disease with Kounis syndrome concern

›ICU criteria

›Intubated airway

›Vasopressor-dependent shock

08Treatment/t71

Epinephrine — first-line for severe cases

›Epinephrine IM — primary agent for severe scombroid

›Indication: hypotension, bronchospasm, angioedema, or upper airway compromise

›Treat as anaphylaxis protocol in severe presentations

›Do not delay for antihistamine first in severe cases

›Dosing

›0.3–0.5 mg IM (1:1,000 solution) anterolateral thigh

›Pediatric dose: 0.01 mg/kg IM, max 0.5 mg

›Repeat dosing

›Every 5–15 minutes if no response or recurrence

›Up to 3 doses before IV epinephrine consideration

›IV epinephrine for refractory shock

›0.1–0.2 mg IV push in cardiac arrest or profound shock

›Infusion: 0.1–1 mcg/kg/min titrated to MAP > 65 mmHg

›Anaphylaxis 2023 Practice Parameter — epinephrine is Class I, first-line

H1 antihistamines

›Diphenhydramine — parenteral H1 blockade

›Dose: 25–50 mg IV or IM

›IV preferred in moderate to severe presentations

›Onset 15–30 minutes IV

›Repeat dosing

›Every 4–6 hours as needed

›Maximum 400 mg/24 hours

›Sedation risk — counsel regarding driving

›Cetirizine — oral H1 for mild presentations

›Dose: 10 mg PO

›Less sedating than diphenhydramine

›Appropriate for mild flushing and headache without hemodynamic compromise

›Alternative: loratadine 10 mg PO or fexofenadine 180 mg PO

›Evidence basis

›H1 antihistamines — first-line pharmacotherapy; ACEP Level B recommendation

›Symptoms typically resolve within 30 minutes of IV antihistamine administration

H2 antihistamines

›Famotidine — adjunctive H2 blockade

›Dose: 20 mg IV over 2 minutes or 20–40 mg PO

›Rational basis: vascular H2 receptors contribute to vasodilation

›Combined H1/H2 blockade recommended over H1 alone

›Evidence basis

›H2 receptors mediate peripheral vasodilation and gastric acid secretion

›Concurrent H2 blockade improves hemodynamic response (ACEP Level B)

›Alternative: ranitidine 50 mg IV (availability may be limited)

Albuterol — bronchospasm management

›Albuterol nebulization

›Dose: 2.5 mg in 3 mL normal saline via nebulizer

›Repeat every 20 minutes for 3 doses if bronchospasm persists

›Continuous nebulization for severe bronchospasm

›Indication: wheeze, respiratory distress, SpO2 < 94% on supplemental oxygen

›Adjunct to epinephrine — not a substitute in anaphylaxis-level presentations

›MDI equivalent: 4–8 puffs via spacer every 20 minutes

Corticosteroids

›Corticosteroids — adjunctive, limited evidence

›Methylprednisolone 125 mg IV for severe presentations

›Consider after epinephrine and antihistamines in severe cases

›May reduce late-phase or biphasic reaction risk

›Evidence limited — used by analogy with anaphylaxis protocols

›Prednisone 40–60 mg PO for moderate-to-severe presentations

›3–5 day course if significant urticaria or angioedema

›Dexamethasone 8–10 mg IV as alternative

IV fluids

›Crystalloid resuscitation for hypotension

›Normal saline or lactated Ringer 1–2 L IV bolus

›Histamine causes massive peripheral vasodilation and relative hypovolemia

›Repeat boluses as needed to MAP > 65 mmHg

›Caution in patients with cardiac or renal comorbidities

›Reassess after each 500 mL bolus

Oxygen supplementation

›Supplemental oxygen

›Nasal cannula 2–4 L/min for SpO2 < 94%

›High-flow oxygen 10–15 L/min via non-rebreather mask for severe bronchospasm

›Intubation and mechanical ventilation for refractory respiratory failure

›Ketamine preferred induction agent — preserves hemodynamics and is bronchodilatory

Vasopressors for refractory shock

›Norepinephrine — vasopressor for epinephrine-refractory shock

›Starting dose: 0.1–0.2 mcg/kg/min continuous IV infusion

›Titrate to MAP > 65 mmHg

›Maximum dose 1–3 mcg/kg/min

›Dopamine alternative if norepinephrine unavailable

›5–20 mcg/kg/min titrated to hemodynamic response

›ICU monitoring required for vasopressor infusions

09Special Populations/sp57

Pregnancy

›Physiologic considerations

›Pregnant patients have increased plasma volume and altered drug distribution

›Histamine-mediated vasodilation may cause more severe hypotension

›Fetal distress from maternal hypotension

›Placental histamine receptors — potential for uteroplacental vasoconstriction

›Medication safety in pregnancy

›Epinephrine — safe in anaphylaxis-equivalent presentations

›Maternal survival takes priority

›Risk of fetal distress from untreated maternal shock exceeds epinephrine risk

›Diphenhydramine — FDA category B; generally safe

›First-generation H1 antihistamines preferred acutely

›Loratadine or cetirizine — FDA category B for mild cases

›Corticosteroids — generally acceptable for severe presentations

›Single-dose IV methylprednisolone risk-benefit favors use in severe anaphylaxis

›Famotidine — FDA category B; acceptable use

›Fetal monitoring

›Obstetric consultation for all symptomatic pregnant patients

›Fetal heart rate monitoring after maternal stabilization

›Third-trimester patients in left lateral decubitus position

Geriatric

›Physiologic vulnerability

›Reduced cardiovascular reserve — tachycardia less well tolerated

›Beta-blocker use may blunt tachycardia response masking severity

›ACE inhibitor use increases angioedema risk

›Reduced renal clearance affects drug dosing

›Polypharmacy — increased risk of isoniazid or MAOI interactions

›Medication considerations in elderly

10Background/b62

Epidemiology

›Global burden

›Scombroid is the most common cause of fish-related food poisoning worldwide

›Exact incidence underreported — many cases diagnosed as fish allergy

›Estimated hundreds of thousands of cases annually globally

›United States burden

›Leading cause of seafood-associated illness outbreaks reported to CDC

›>80% of fish consumed in the US is imported — cold-chain vulnerability

›ICD-10 coding: T61.1XXA (ingestion of other fish and shellfish)

›ICD-10 T61.11XA: scombroid fish poisoning, initial encounter

›Species and geography

›Scombridae family: tuna, mackerel, bonito, skipjack

›Non-scombroid species also implicated: mahi-mahi, bluefish, amberjack, anchovy

›Pacific and tropical waters — higher ambient temperatures accelerate spoilage

›High-risk settings

›Restaurants (limited cold-chain control)

›Imported fresh fish from tropical regions

›Home preparation of freshly caught fish without prompt refrigeration

Pathophysiology

›Histamine production mechanism

›Bacterial decarboxylation of L-histidine to histamine

›Key organisms: Morganella morganii, Klebsiella pneumoniae, Enterobacter aerogenes

›Most active at temperatures >4.4°C (40°F) — standard refrigeration prevents it

›Histamine is heat-stable — not destroyed by cooking, canning, freezing, or smoking

›Dark-fleshed fish have higher free L-histidine content

›Dark muscle tissue metabolically active with high histidine pools

›Explains species predilection for scombroid poisoning

›Histamine toxicology

›FDA action level >50 mg histamine per 100g fish

›Typical contaminated fish: 100–4,000 mg/100g in severe outbreaks

›Histamine acts on H1, H2, and H3 receptors

›H1: smooth muscle contraction, increased vascular permeability, bronchoconstriction

›H2: gastric acid secretion, peripheral vasodilation, positive chronotropy

›H3: central nervous system effects — headache, dizziness

›Non-immunologic mechanism — no prior sensitization required

›Distinguishes fundamentally from IgE-mediated allergy

›Tryptase remains normal — no mast cell degranulation

›Co-factor amplification

›Diamine oxidase (DAO) normally degrades ingested histamine in gut mucosa

›DAO inhibition by isoniazid dramatically increases systemic histamine exposure

›Histamine N-methyltransferase provides secondary metabolic pathway

›Scombrotoxin complex — biogenic amines beyond histamine

›Putrescine and cadaverine may potentiate histamine toxicity

›Exact co-toxin contributions remain under investigation

Therapeutic Considerations

›Mechanism-based treatment rationale

›H1 blockade: diphenhydramine blocks H1-mediated bronchoconstriction, pruritus, urticaria

›Rapid IV administration achieves symptom control within 15–30 minutes

›H2 blockade: famotidine blocks vascular H2 receptors reducing vasodilation

›Synergistic with H1 blockade for hemodynamic stabilization

›Epinephrine: reverses bronchospasm via beta-2 agonism and restores vascular tone via alpha-1

›Bypasses receptor blockade to directly reverse physiologic effects

›Key therapeutic pitfall — incorrect fish allergy labeling

›Prescribing epinephrine auto-injector for future fish avoidance is incorrect

›Patients do NOT need to avoid fish — the problem is improper storage

›Incorrect allergy labeling causes unnecessary dietary restriction and anxiety

›Ridolo et al., Current Opinion in Allergy and Clinical Immunology 2016

›Public health intervention is the appropriate systemic response

›Health department notification

›FDA investigation of implicated fish batch

›Natural history

›Self-limited in the vast majority of cases

›Symptom duration: 6–12 hours typical, rarely up to 48 hours

›Mild cases may resolve spontaneously without treatment

›No long-term sequelae reported

11Patient Discharge Instructions/pdi43

copy discharge instructions

›What happened to you

›You were diagnosed with scombroid fish poisoning, also called histamine fish poisoning

›This is NOT a fish allergy — you are NOT allergic to fish

›It was caused by eating fish that was improperly stored or refrigerated

›Bacteria in the fish produced a chemical called histamine before you ate it

›Cooking does not destroy histamine — the fish may have looked, smelled, and tasted normal

›Your current treatment

›You received antihistamine medication to block the effects of histamine

›This is what treats scombroid poisoning

›Your symptoms should continue to improve over the next several hours

›Most people recover fully within 6–12 hours

›Occasionally symptoms last up to 48 hours

›Medications to take at home

›Take the antihistamine prescribed or purchased over-the-counter as directed

›Diphenhydramine (Benadryl) 25–50 mg every 6 hours as needed — may cause drowsiness

›OR cetirizine (Reactine/Zyrtec) 10 mg once daily — less drowsy option

›Do not drive or operate machinery if taking diphenhydramine

›If prescribed famotidine (Pepcid), take it with the antihistamine

›Foods and activities to avoid today

›Rest and avoid strenuous activity for the remainder of the day

›Clear fluids if still experiencing nausea — progress to regular diet as tolerated

›Avoid alcohol — it can worsen flushing and interact with antihistamines

›Eating fish in the future

›You CAN eat fish in the future — this was not an allergy

›To prevent this from happening again, ensure fish is stored correctly

›Fresh fish must be kept at below 3.3 degrees Celsius (38 degrees Fahrenheit) or frozen immediately after purchase or catch

›If fish tastes peppery, sharp, or unusual, do not eat it

12References/r39

Guidelines and key sources

›CDC Yellow Book 2025 — Food Poisoning from Marine Toxins (Ansdell)

›Primary clinical reference for scombroid epidemiology, diagnosis, and treatment

›Source: cdc.gov/yellow-book

›Morrow JD et al. — Evidence That Histamine Is the Causative Toxin of Scombroid-Fish Poisoning

›NEJM 1991 — established histamine causation with direct measurement

›PMID: reference classic study

›Feng C, Teuber S, Gershwin ME — Histamine (Scombroid) Fish Poisoning: A Comprehensive Review

›Clinical Reviews in Allergy and Immunology 2016

›PMID: 25876709

›Ridolo E et al. — Scombroid Syndrome: It Seems to Be Fish Allergy But... It Isn't

›Current Opinion in Allergy and Clinical Immunology 2016

›PMID: 27466827

›Ricci G et al. — Tryptase Serum Level as a Possible Indicator of Scombroid Syndrome

›Clinical Toxicology 2010 — validated tryptase as differentiating biomarker

›PMID: 20230333

Drug interaction and toxicology references

›Miki M et al. — Outbreak of Histamine Poisoning After Ingestion of Ground Saury Paste in TB Ward

›Internal Medicine 2005 — isoniazid-histamine interaction documented

›PMID: 16357449

›Morinaga S et al. — Histamine Poisoning After Ingestion of Spoiled Raw Tuna in Patient Taking Isoniazid

›Internal Medicine 1997

›PMID: 9144013

›Self TH et al. — Isoniazid Drug and Food Interactions

›American Journal of the Medical Sciences 1999 — comprehensive DAO inhibition review

›PMID: 10334118

›Hui JY, Taylor SL — Inhibition of in Vivo Histamine Metabolism by Pharmacologic Inhibitors

›Toxicology and Applied Pharmacology 1985 — mechanistic DAO inhibition data

Learn More: Scombroid Fish Poisoning→

Comprehensive Clinical Review

Structured, evidence-informed, long-form analysis for deeper understanding.

Evidence & Review

Reviewed by SymptomDx Medical Team · Last reviewed August 18, 2026

SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.